CardiaLen

About:

CardiaLen develops and commercializes pain-free cardioversion therapies for atrial fibrillation.

Top Investors: Qiming Venture Partners, National Institutes of Health, Cultivation Capital, BioGenerator, Broadview Ventures

Description:

CardiaLen develops and commercializes pain-free cardioversion therapies for atrial fibrillation. The company is developing implantable low-energy (low voltage) pain-free atrial cardioverters to help address the major unmet needs of this condition. It was founded in 2008 and headquartered in Minneapolis, Minnesota.

Total Funding Amount:

$34.8M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Minneapolis, Minnesota, United States

Founded Date:

2008-01-01

Contact Email:

info(AT)cardialen.com

Founders:

Randy H. Weiss

Number of Employees:

11-50

Last Funding Date:

2021-06-24

IPO Status:

Private

Industries: